7kcx

<table><tr><td colspan='2'>[[7kcx]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Staphylococcus_aureus_subsp._aureus_COL Staphylococcus aureus subsp. aureus COL]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7KCX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7KCX FirstGlance]. <br>

== Function ==

[https://www.uniprot.org/uniprot/A0A0H2WY27_STAAC A0A0H2WY27_STAAC]

<div style="background-color:#fffaf0;">

== Publication Abstract from PubMed ==

BACKGROUND: PBP4, a low-molecular-weight PBP in Staphylococcus aureus, is not considered to be a classical mediator of beta-lactam resistance. Previous studies carried out by our group with laboratory strains of S. aureus demonstrated the ability of PBP4 to produce beta-lactam resistance through mutations associated with the pbp4 promoter and/or gene. Recent studies of beta-lactam-resistant clinical isolates of S. aureus have reported similar mutations associated with pbp4. OBJECTIVES: To determine if pbp4-associated mutations reported among clinical strains of S. aureus mediate beta-lactam resistance. METHODS: The pbp4 promoters and genes bearing mutations from clinical isolates were cloned into a heterologous host. Reporter, growth and Bocillin assays were performed to assess their role in beta-lactam resistance. X-ray crystallography was used to obtain acyl-enzyme intermediate structures of the WT and mutant PBP4 with nafcillin and cefoxitin. RESULTS: Of the five strains that contained pbp4 promoter mutations, three strains exhibited enhanced expression of PBP4. The R200L mutation in pbp4 resulted in increased survival in the presence of the beta-lactams nafcillin and cefoxitin. Further, introduction of either a promoter or a gene mutation into the genome of a WT host increased the ability of the strains to resist the action of beta-lactams. The four high-resolution X-ray structures presented demonstrate the binding pose of the beta-lactams tested and provide hints for further drug development. CONCLUSIONS: Mutations associated with the pbp4 promoter and pbp4 gene altered protein activity and mediated beta-lactam resistance among the clinically isolated strains that were studied.

PBP4-mediated beta-lactam resistance among clinical strains of Staphylococcus aureus.,Satishkumar N, Alexander JAN, Poon R, Buggeln E, Argudin MA, Strynadka NCJ, Chatterjee SS J Antimicrob Chemother. 2021 Jun 21. pii: 6307153. doi: 10.1093/jac/dkab201. PMID:34151961<ref>PMID:34151961</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>

</div>

<div class="pdbe-citations 7kcx" style="background-color:#fffaf0;"></div>

== References ==

<references/>

[[Category: Staphylococcus aureus subsp. aureus COL]]